false000078516100007851612025-02-062025-02-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 6, 2025
Encompass Health Corporation
(Exact name of Registrant as specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| | | | | |
| 001-10315 | 63-0860407 |
| (Commission File Number) | (IRS Employer Identification No.) |
| |
9001 Liberty Parkway, Birmingham, Alabama 35242
(Address of Principal Executive Offices, Including Zip Code)
(205) 967-7116
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | EHC | New York Stock Exchange |
The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 2.02. Results of Operations and Financial Condition.
On February 6, 2025, Encompass Health Corporation (“Encompass Health” or the “Company”) issued a press release reporting the financial results of the Company for the three months and year ended December 31, 2024. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
The Company uses “same-store” comparisons to explain the changes in certain performance metrics within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions and capacity expansions (including the addition of satellite and remote hospitals) in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.
ITEM 7.01. Regulation FD Disclosure.
See Item 2.02, “Results of Operations and Financial Condition,” above.
In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Friday, February 7, 2025 is attached to this report as Exhibit 99.2 and incorporated herein by reference.
Note Regarding Presentation of Non-GAAP Financial Measures
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.
The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.
The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct cash on hand from consolidated total debt. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments, subject to certain limitations, resulting from (1) dispositions and repayments or incurrence of debt and (2) investments, acquisitions, mergers, amalgamations, consolidations and other operational changes to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. The Company reconciles Adjusted EBITDA to net cash provided by operating activities and net income in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.
The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 9, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2024 (the “2024 Form 10‑K”), when filed. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.
In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment of debt and acquisitions, and (7) any restructuring charges and certain pro-forma cost savings and synergies related to transactions and initiatives, which in the aggregate are not in excess of 25% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.
The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company's ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.
Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2024 Form 10‑K, when filed.
The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company's definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, distributions to noncontrolling interests, and certain items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2024 Form 10‑K, when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.
Forward-Looking Statements
The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the business model, strategy, outlook and guidance, growth targets, labor cost trends, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results, ability to return value to its shareholders, projected capital expenditures and development plans, leverage ratio, guidance considerations, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.
There can be no assurance that any estimates, projections, or forward-looking statements will be realized.
All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.
You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2024 Form 10‑K, when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| | | | | | | | |
| Exhibit Number | | Description |
| | |
| | |
| 104 | | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| ENCOMPASS HEALTH CORPORATION |
| By: | /S/ DOUGLAS E. COLTHARP |
| Name: | Douglas E. Coltharp |
| Title: | Executive Vice President and Chief Financial Officer |
Dated: February 6, 2025
| | | | | |
| Media Contact | February 6, 2025 |
| Polly Manuel, 205 969-4532 | |
| polly.manuel@encompasshealth.com | |
| |
| Investor Relations Contact | |
| Mark Miller, 205 970-5860 | |
| mark.miller@encompasshealth.com | |
Encompass Health reports results for fourth quarter 2024
and issues 2025 guidance
BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the fourth quarter ended December 31, 2024.
Summary results | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | Growth |
| Q4 2024 | | Q4 2023 | | Dollars | | Percent |
| (In Millions, Except Per Share Data) |
| Net operating revenue | $ | 1,405.0 | | | $ | 1,246.8 | | | $ | 158.2 | | | 12.7 | % |
Income from continuing operations attributable to Encompass Health per diluted share | 1.18 | | | 0.94 | | | 0.24 | | | 25.5 | % |
| Adjusted earnings per share | 1.17 | | | 0.95 | | | 0.22 | | | 23.2 | % |
Cash flows provided by operating activities | 278.8 | | | 201.0 | | | 77.8 | | | 38.7 | % |
| Adjusted EBITDA | 289.6 | | | 255.0 | | | 34.6 | | | 13.6 | % |
| Adjusted free cash flow | 190.5 | | | 93.5 | | | 97.0 | | | 103.7 | % |
| | | | | | | |
| (Actual Amounts) | | | | | |
| Discharges | 63,839 | | 59,247 | | | | 7.8 | % |
| Same-store discharge growth | | | | | | | 5.8 | % |
| Net patient revenue per discharge | $ | 21,399 | | | $ | 20,538 | | | | | 4.2 | % |
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
•Revenue growth of 12.7% resulted primarily from discharge growth of 7.8%, including same-store growth of 5.8%. Net patient revenue per discharge grew 4.2%.
•Cash flows provided by operating activities increased 38.7% to $278.8 million, primarily due to an increase in net income and favorable change in working capital partly offset by higher cash tax payments.
•Adjusted EBITDA increased 13.6%, primarily from increased revenue.
“The fourth quarter was a very strong finish to 2024,” said President and Chief Executive Officer of Encompass Health Mark Tarr. “Discharge growth of 7.8% facilitated an increase of 12.7% in net operating revenue and an increase of 13.6% in Adjusted EBITDA. For the full year, net operating revenue increased 11.9% and Adjusted EBITDA grew 13.7%.”
“In 2024, we increased our capacity by a total of 427 beds through new hospitals and bed additions to existing hospitals. Our value proposition and operating strategy continue to be validated and we remain bullish on the long-term prospects of our business.”
2025 Guidance
The Company provided the following guidance for 2025.
| | | | | | | | |
| 2025 Guidance | |
| (In Millions, Except Per Share Data) |
| Net operating revenue | $5,800 to $5,900 | |
| Adjusted EBITDA | $1,160 to $1,200 | |
| Adjusted earnings per share from continuing operations attributable to Encompass Health | $4.67 to $4.96 | |
For considerations regarding the Company’s 2025 guidance, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 10:00 a.m. Eastern Time on Friday, February 7, 2025 to discuss its results for the fourth quarter of 2024. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 800 579-2543 and giving the conference ID EHCQ424. International callers should dial 785 424-1789 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 166 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World’s Most Admired CompaniesTM, Becker’s Hospital Review’s 150 Top Places to Work in Healthcare and Forbes’ Most Trusted Companies in America.1 For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
1 Fortune © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World’s Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.
Other information
The information in this press release is summarized and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”), when filed, as well as the Company’s Current Report on Form 8-K filed on February 6, 2025 (the “Q4 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its February 7, 2025 earnings call.
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q4 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q4 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.
Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.
However, the following reasonably estimable GAAP measures for 2025 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:
•Interest expense and amortization of debt discounts and fees - approximately $125 million
•Amortization of debt-related items - approximately $10 million
The Q4 Earnings Form 8-K and, when filed, the 2024 Form 10-K can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| For the Three Months Ended December 31, | | For the Year Ended December 31, |
| | 2024 | | 2023 | | 2024 | | 2023 |
| (In Millions, Except Per Share Data) |
| Net operating revenues | $ | 1,405.0 | | | $ | 1,246.8 | | | $ | 5,373.2 | | | $ | 4,801.2 | |
| Operating expenses: | | | | | | | |
| Salaries and benefits | 756.8 | | | 676.3 | | | 2,901.0 | | | 2,600.1 | |
| Other operating expenses | 206.4 | | | 184.8 | | | 802.6 | | | 719.1 | |
| Occupancy costs | 14.7 | | | 14.0 | | | 57.3 | | | 56.3 | |
| Supplies | 62.3 | | | 58.6 | | | 239.0 | | | 218.3 | |
| General and administrative expenses | 54.5 | | | 53.1 | | | 209.2 | | | 201.7 | |
| Depreciation and amortization | 78.0 | | | 70.1 | | | 299.6 | | | 273.9 | |
| Total operating expenses | 1,172.7 | | | 1,056.9 | | | 4,508.7 | | | 4,069.4 | |
| Loss on early extinguishment of debt | 0.2 | | | — | | | 0.6 | | | — | |
| Interest expense and amortization of debt discounts and fees | 33.0 | | | 34.9 | | | 137.4 | | | 143.5 | |
| Other income | (2.1) | | | (8.9) | | | (20.1) | | | (15.7) | |
| Equity in net income of nonconsolidated affiliates | (0.2) | | | (0.9) | | | (3.0) | | | (3.2) | |
| Income from continuing operations before income tax expense | 201.4 | | | 164.8 | | | 749.6 | | | 607.2 | |
| Provision for income tax expense | 37.6 | | | 37.2 | | | 150.2 | | | 132.2 | |
| Income from continuing operations | 163.8 | | | 127.6 | | | 599.4 | | | 475.0 | |
| Income (loss) from discontinued operations, net of tax | 0.4 | | | (8.5) | | | (2.8) | | | (12.0) | |
| Net and comprehensive income | 164.2 | | | 119.1 | | | 596.6 | | | 463.0 | |
| | | | | | | |
| | | | | | | |
| Less: Net and comprehensive income attributable to noncontrolling interests | (43.3) | | | (31.5) | | | (140.9) | | | (111.0) | |
| Net and comprehensive income attributable to Encompass Health | $ | 120.9 | | | $ | 87.6 | | | $ | 455.7 | | | $ | 352.0 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Weighted average common shares outstanding: | | | | | | | |
| Basic | 100.0 | | | 99.5 | | | 99.9 | | | 99.5 | |
| Diluted | 102.3 | | | 101.5 | | | 102.2 | | | 101.3 | |
Earnings per common share: | | | | | | | |
Basic earnings per share attributable to Encompass Health common shareholders: | | | | | | | |
Continuing operations | $ | 1.20 | | | $ | 0.96 | | | $ | 4.56 | | | $ | 3.63 | |
Discontinued operations | — | | | (0.09) | | | (0.03) | | | (0.12) | |
Net income | $ | 1.20 | | | $ | 0.87 | | | $ | 4.53 | | | $ | 3.51 | |
Diluted earnings per share attributable to Encompass Health common shareholders: | | | | | | | |
Continuing operations | $ | 1.18 | | | $ | 0.94 | | | $ | 4.49 | | | $ | 3.59 | |
Discontinued operations | — | | | (0.08) | | | (0.03) | | | (0.12) | |
Net income | $ | 1.18 | | | $ | 0.86 | | | $ | 4.46 | | | $ | 3.47 | |
| | | | | | | |
| Amounts attributable to Encompass Health common shareholders: | | | | | | | |
| Income from continuing operations | $ | 120.5 | | | $ | 96.1 | | | $ | 458.5 | | | $ | 364.0 | |
| Income (loss) from discontinued operations, net of tax | 0.4 | | | (8.5) | | | (2.8) | | | (12.0) | |
| Net income attributable to Encompass Health | $ | 120.9 | | | $ | 87.6 | | | $ | 455.7 | | | $ | 352.0 | |
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
| | | | | | | | | | | | |
| As of December 31, 2024 | | As of December 31, 2023 | |
| | (In Millions) | |
| Assets | | | | |
| Current assets: | | | | |
| Cash and cash equivalents | $ | 85.4 | | | $ | 69.1 | | |
| Restricted cash | 37.7 | | | 35.1 | | |
| Accounts receivable | 598.8 | | | 611.6 | | |
| Prepaid expenses | 42.3 | | | 34.5 | | |
| Other current assets | 122.7 | | | 91.5 | | |
| Total current assets | 886.9 | | | 841.8 | | |
| Property and equipment, net | 3,643.1 | | | 3,301.0 | | |
| Operating lease right-of-use assets | 203.7 | | | 208.5 | | |
| Goodwill | 1,284.0 | | | 1,281.3 | | |
| Intangible assets, net | 297.8 | | | 278.2 | | |
| | | | |
| Other long-term assets | 219.2 | | | 191.6 | | |
| Total assets | $ | 6,534.7 | | | $ | 6,102.4 | | |
| Liabilities and Shareholders’ Equity | | | | |
| Current liabilities: | | | | |
| Current portion of long-term debt | $ | 138.6 | | | $ | 24.8 | | |
| Current operating lease liabilities | 26.3 | | | 24.1 | | |
| Accounts payable | 171.0 | | | 170.0 | | |
| Accrued payroll | 227.9 | | | 207.5 | | |
| Accrued interest payable | 38.6 | | | 42.6 | | |
| | | | |
| Other current liabilities | 238.6 | | | 187.4 | | |
| Total current liabilities | 841.0 | | | 656.4 | | |
| Long-term debt, net of current portion | 2,359.2 | | | 2,687.8 | | |
| Long-term operating lease liabilities | 189.7 | | | 196.1 | | |
| Self-insured risks | 138.6 | | | 131.8 | | |
| Deferred income tax liabilities | 105.2 | | | 87.0 | | |
| Other long-term liabilities | 51.8 | | | 46.1 | | |
| Total liabilities | 3,685.5 | | | 3,805.2 | | |
| Commitments and contingencies | | | | |
| | | | |
| Redeemable noncontrolling interests | 56.5 | | | 42.0 | | |
| Shareholders’ equity: | | | | |
| Encompass Health shareholders’ equity | 2,067.0 | | | 1,647.5 | | |
| Noncontrolling interests | 725.7 | | | 607.7 | | |
| Total shareholders’ equity | 2,792.7 | | | 2,255.2 | | |
| Total liabilities and shareholders’ equity | $ | 6,534.7 | | | $ | 6,102.4 | | |
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| | | | | | | | | | | | |
| | For the Year Ended December 31, | |
| | 2024 | | 2023 | |
| | (In Millions) | |
| Cash flows from operating activities: | | | | |
| Net income | $ | 596.6 | | | $ | 463.0 | | |
| Loss from discontinued operations, net of tax | 2.8 | | | 12.0 | | |
| Adjustments to reconcile net income to net cash provided by operating activities— | | | | |
| | | | |
| Depreciation and amortization | 299.6 | | | 273.9 | | |
| Amortization of debt-related items | 9.7 | | | 9.5 | | |
| Loss on early extinguishment of debt | 0.6 | | | — | | |
| Equity in net income of nonconsolidated affiliates | (3.0) | | | (3.2) | | |
| Distributions from nonconsolidated affiliates | 4.0 | | | 1.6 | | |
| Stock-based compensation | 48.3 | | | 50.6 | | |
| Deferred tax expense | 10.7 | | | 3.9 | | |
| | | | |
| | | | |
| Other, net | 14.7 | | | 5.2 | | |
| Change in assets and liabilities, net of acquisitions— | | | | |
| Accounts receivable | 3.0 | | | (22.4) | | |
| Prepaid expenses and other assets | (57.3) | | | 6.1 | | |
| Accounts payable | 3.0 | | | 11.8 | | |
| Accrued payroll | 20.4 | | | 39.2 | | |
| | | | |
| Other liabilities | 52.8 | | | 15.6 | | |
| Net cash used in operating activities of discontinued operations | (3.1) | | | (16.0) | | |
| Total adjustments | 403.4 | | | 375.8 | | |
| Net cash provided by operating activities | 1,002.8 | | | 850.8 | | |
| Cash flows from investing activities: | | | | |
| | | | |
| Purchases of property, equipment, and intangible assets | (642.5) | | | (583.1) | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Proceeds from sale of restricted investments | 18.9 | | | 7.4 | | |
| Purchase of restricted investments | (22.5) | | | (23.0) | | |
| Other, net | (7.2) | | | (4.1) | | |
| | | | |
| Net cash used in investing activities | (653.3) | | | (602.8) | | |
| | | | |
| | | | |
| | |
| | | | |
| | |
| Cash flows from financing activities: | | | | |
| | | | |
| Principal borrowings on notes | 15.0 | | | 20.0 | | |
| | | | |
| Principal payments on debt, including pre-payments | (255.2) | | | (7.2) | | |
| Borrowings on revolving credit facility | 80.0 | | | 60.0 | | |
| Payments on revolving credit facility | (60.0) | | | (115.0) | | |
| Principal payments under finance lease obligations | (21.8) | | | (41.1) | | |
| Debt amendment costs | (0.1) | | | (0.1) | | |
| Taxes paid on behalf of employees for shares withheld | (12.1) | | | (8.2) | | |
| | | | |
| | | | |
| Contributions from noncontrolling interests of consolidated affiliates | 140.4 | | | 68.3 | | |
| Dividends paid on common stock | (62.8) | | | (60.4) | | |
| Distributions paid to noncontrolling interests of consolidated affiliates | (125.0) | | | (114.7) | | |
| Repurchases of common stock, including fees and expenses | (31.1) | | | — | | |
| Other, net | 2.1 | | | 1.2 | | |
| | | | |
| Net cash used in financing activities | (330.6) | | | (197.2) | | |
| Increase in cash, cash equivalents, and restricted cash | 18.9 | | | 50.8 | | |
| Cash, cash equivalents, and restricted cash at beginning of period | 104.2 | | | 53.4 | | |
| Cash, cash equivalents, and restricted cash at end of period | $ | 123.1 | | | $ | 104.2 | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | |
| | | | |
| | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Encompass Health Corporation and Subsidiaries
Supplemental Information
Earnings Per Share
| | | | | | | | | | | | | | | | | | | | | | | |
| Q4 | | Year Ended |
| 2024 | | 2023 | | 2024 | | 2023 |
| (In Millions, Except Per Share Data) |
| Adjusted EBITDA | $ | 289.6 | | | $ | 255.0 | | | $ | 1,103.7 | | | $ | 971.1 | |
Depreciation and amortization | (78.0) | | | (70.1) | | | (299.6) | | | (273.9) | |
Interest expense and amortization of debt discounts and fees | (33.0) | | | (34.9) | | | (137.4) | | | (143.5) | |
| Stock-based compensation | (12.5) | | | (13.4) | | | (48.3) | | | (50.6) | |
| Loss on disposal or impairment of assets | (6.1) | | | (6.1) | | | (17.4) | | | (9.8) | |
| 160.0 | | | 130.5 | | | 601.0 | | | 493.3 | |
| Items not indicative of ongoing operating performance: | | | | | | | |
| Loss on early extinguishment of debt | (0.2) | | | — | | | (0.6) | | | — | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| State regulatory change impact on noncontrolling interests | — | | | — | | | — | | | 2.2 | |
Change in fair market value of equity securities | (1.7) | | | 2.8 | | | 1.0 | | | 0.7 | |
| Asset impairment impact on noncontrolling interests | — | | | — | | | 7.3 | | | — | |
| | | | | | | |
| Pre-tax income | 158.1 | | | 133.3 | | | 608.7 | | | 496.2 | |
Income tax expense | (37.6) | | | (37.2) | | | (150.2) | | | (132.2) | |
Income from continuing operations (1) | $ | 120.5 | | | $ | 96.1 | | | $ | 458.5 | | | $ | 364.0 | |
| | | | | | | |
| Basic shares | 100.0 | | | 99.5 | | | 99.9 | | | 99.5 | |
| Diluted shares | 102.3 | | | 101.5 | | | 102.2 | | | 101.3 | |
| | | | | | | |
Basic earnings per share (1) | $ | 1.20 | | | $ | 0.96 | | | $ | 4.56 | | | $ | 3.63 | |
Diluted earnings per share (1) | $ | 1.18 | | | $ | 0.94 | | | $ | 4.49 | | | $ | 3.59 | |
(1)Income from continuing operations attributable to Encompass Health
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share
| | | | | | | | | | | | | | | | | | | | | | | |
| Q4 | | Year Ended |
| 2024 | | 2023 | | 2024 | | 2023 |
| | | | | | | |
| Earnings per share, as reported | $ | 1.18 | | | $ | 0.94 | | | $ | 4.49 | | | $ | 3.59 | |
| Adjustments, net of tax: | | | | | | | |
| | | | | | | |
| Asset impairment impact | — | | | — | | | 0.02 | | | — | |
| | | | | | | |
| | | | | | | |
Income tax adjustments | (0.03) | | | 0.03 | | | (0.08) | | | 0.03 | |
| State regulatory change impact | — | | | — | | | — | | | 0.03 | |
| | | | | | | |
Change in fair market value of equity securities | 0.01 | | | (0.02) | | | (0.01) | | | — | |
| | | | | | | |
| | | | | | | |
Adjusted earnings per share* | $ | 1.17 | | | $ | 0.95 | | | $ | 4.43 | | | $ | 3.64 | |
* Adjusted EPS may not sum due to rounding.
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA
| | | | | | | | | | | | | | | | | | | | | | | |
| Q4 | | Year Ended |
| 2024 | | 2023 | | 2024 | | 2023 |
| (In Millions) |
Net cash provided by operating activities | $ | 278.8 | | | $ | 201.0 | | | $ | 1,002.8 | | | $ | 850.8 | |
Interest expense and amortization of debt discounts and fees | 33.0 | | | 34.9 | | | 137.4 | | | 143.5 | |
| (Loss) gain on sale of investments, excluding impairments | (3.1) | | | 5.5 | | | 2.7 | | | 4.6 | |
Equity in net income of nonconsolidated affiliates | 0.2 | | | 0.9 | | | 3.0 | | | 3.2 | |
Net income attributable to noncontrolling interests in continuing operations | (43.3) | | | (31.5) | | | (140.9) | | | (111.0) | |
Amortization of debt-related items | (2.4) | | | (2.4) | | | (9.7) | | | (9.5) | |
Distributions from nonconsolidated affiliates | (0.9) | | | (1.0) | | | (4.0) | | | (1.6) | |
| Current portion of income tax expense | 29.0 | | | 30.4 | | | 139.5 | | | 128.3 | |
| Change in assets and liabilities | (2.8) | | | 8.6 | | | (21.9) | | | (50.3) | |
| Cash (provided by) used in operating activities of discontinued operations | (0.6) | | | 11.4 | | | 3.1 | | | 16.0 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| State regulatory change impact on noncontrolling interests | — | | | — | | | — | | | (2.2) | |
| | | | | | | |
| Asset impairment impact on noncontrolling interests | — | | | — | | | (7.3) | | | — | |
| Change in fair market value of equity securities | 1.7 | | | (2.8) | | | (1.0) | | | (0.7) | |
| | | | | | | |
| Adjusted EBITDA | $ | 289.6 | | | $ | 255.0 | | | $ | 1,103.7 | | | $ | 971.1 | |
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Three Months Ended December 31, 2024 |
| | | | | | | | | | | Adjustments | | | | | | |
| As Reported | | | | | | | | | | Loss on Early Extinguishment of Debt | | Income Tax Adjustments | | | | | | | | Change in Fair Market Value of Equity Securities | | | | | | As Adjusted |
| (In Millions, Except Per Share Amounts) |
| Adjusted EBITDA* | $ | 289.6 | | | | | | | | | | | $ | — | | | $ | — | | | | | | | | | $ | — | | | | | | | $ | 289.6 | |
| Depreciation and amortization | (78.0) | | | | | | | | | | | — | | | — | | | | | | | | | — | | | | | | | (78.0) | |
Interest expense and amortization of debt discounts and fees | (33.0) | | | | | | | | | | | — | | | — | | | | | | | | | — | | | | | | | (33.0) | |
| Stock-based compensation | (12.5) | | | | | | | | | | | — | | | — | | | | | | | | | — | | | | | | | (12.5) | |
| Loss on disposal or impairment of assets | (6.1) | | | | | | | | | | | — | | | — | | | | | | | | | — | | | | | | | (6.1) | |
| Loss on early extinguishment of debt | (0.2) | | | | | | | | | | | 0.2 | | | — | | | | | | | | | — | | | | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair market value of equity securities | (1.7) | | | | | | | | | | | — | | | — | | | | | | | | | 1.7 | | | | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Income from continuing operations before income tax expense | 158.1 | | | | | | | | | | | 0.2 | | | — | | | | | | | | | 1.7 | | | | | | | 160.0 | |
| Provision for income tax expense | (37.6) | | | | | | | | | | | (0.1) | | | (2.6) | | | | | | | | | (0.4) | | | | | | | (40.7) | |
Income from continuing operations attributable to Encompass Health | $ | 120.5 | | | | | | | | | | | $ | 0.1 | | | $ | (2.6) | | | | | | | | | $ | 1.3 | | | | | | | $ | 119.3 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Diluted earnings per share from continuing operations** | $ | 1.18 | | | | | | | | | | | $ | — | | | $ | (0.03) | | | | | | | | | $ | 0.01 | | | | | | | $ | 1.17 | |
| Diluted shares used in calculation | 102.3 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Three Months Ended December 31, 2023 |
| | | | | | | | | | | | | Adjustments | | | | | | |
| As Reported | | | | | | | | | | | | Income Tax Adjustments | | | | | | | | Change in Fair Market Value of Equity Securities | | | | | | As Adjusted |
| (In Millions, Except Per Share Amounts) |
| Adjusted EBITDA* | $ | 255.0 | | | | | | | | | | | | | $ | — | | | | | | | | | $ | — | | | | | | | $ | 255.0 | |
| Depreciation and amortization | (70.1) | | | | | | | | | | | | | — | | | | | | | | | — | | | | | | | (70.1) | |
Interest expense and amortization of debt discounts and fees | (34.9) | | | | | | | | | | | | | — | | | | | | | | | — | | | | | | | (34.9) | |
| Stock-based compensation | (13.4) | | | | | | | | | | | | | — | | | | | | | | | — | | | | | | | (13.4) | |
| Loss on disposal or impairment of assets | (6.1) | | | | | | | | | | | | | — | | | | | | | | | — | | | | | | | (6.1) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair market value of equity securities | 2.8 | | | | | | | | | | | | | — | | | | | | | | | (2.8) | | | | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Income from continuing operations before income tax expense | 133.3 | | | | | | | | | | | | | — | | | | | | | | | (2.8) | | | | | | | 130.5 | |
| Provision for income tax expense | (37.2) | | | | | | | | | | | | | 2.9 | | | | | | | | | 0.7 | | | | | | | (33.6) | |
Income from continuing operations attributable to Encompass Health | $ | 96.1 | | | | | | | | | | | | | $ | 2.9 | | | | | | | | | $ | (2.1) | | | | | | | $ | 96.9 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Diluted earnings per share from continuing operations** | $ | 0.94 | | | | | | | | | | | | | $ | 0.03 | | | | | | | | | $ | (0.02) | | | | | | | $ | 0.95 | |
| Diluted shares used in calculation | 101.5 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Year Ended December 31, 2024 |
| | | | | | | | | Adjustments | | | | | | |
| As Reported | | | | | | | | Asset Impairment Impact | | Loss on Early Extinguishment of Debt | | Income Tax Adjustments | | | | | | | | Change in Fair Market Value of Equity Securities | | | | | | As Adjusted |
| (In Millions, Except Per Share Amounts) |
| Adjusted EBITDA* | $ | 1,103.7 | | | | | | | | | $ | — | | | $ | — | | | $ | — | | | | | | | | | $ | — | | | | | | | $ | 1,103.7 | |
| Depreciation and amortization | (299.6) | | | | | | | | | — | | | — | | | — | | | | | | | | | — | | | | | | | (299.6) | |
Interest expense and amortization of debt discounts and fees | (137.4) | | | | | | | | | — | | | — | | | — | | | | | | | | | — | | | | | | | (137.4) | |
| Stock-based compensation | (48.3) | | | | | | | | | — | | | — | | | — | | | | | | | | | — | | | | | | | (48.3) | |
| Loss on disposal or impairment of assets | (17.4) | | | | | | | | | 10.4 | | | — | | | — | | | | | | | | | — | | | | | | | (7.0) | |
| Loss on early extinguishment of debt | (0.6) | | | | | | | | | — | | | 0.6 | | | — | | | | | | | | | — | | | | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair market value of equity securities | 1.0 | | | | | | | | | — | | | — | | | — | | | | | | | | | (1.0) | | | | | | | — | |
| Asset impairment impact on noncontrolling interests | 7.3 | | | | | | | | | (7.3) | | | — | | | — | | | | | | | | | — | | | | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Income from continuing operations before income tax expense | 608.7 | | | | | | | | | 3.1 | | | 0.6 | | | — | | | | | | | | | (1.0) | | | | | | | 611.4 | |
| Provision for income tax expense | (150.2) | | | | | | | | | (1.3) | | | (0.2) | | | (7.7) | | | | | | | | | 0.3 | | | | | | | (159.1) | |
Income from continuing operations attributable to Encompass Health | $ | 458.5 | | | | | | | | | $ | 1.8 | | | $ | 0.4 | | | $ | (7.7) | | | | | | | | | $ | (0.7) | | | | | | | $ | 452.3 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Diluted earnings per share from continuing operations** | $ | 4.49 | | | | | | | | | $ | 0.02 | | | $ | — | | | $ | (0.08) | | | | | | | | | $ | (0.01) | | | | | | | $ | 4.43 | |
| Diluted shares used in calculation | 102.2 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| For the Year Ended December 31, 2023 |
| | | | | | | Adjustments | | | | | | |
| As Reported | | | | | | State Regulatory Change Impact | | | | | | Income Tax Adjustments | | | | | | | | Change in Fair Market Value of Equity Securities | | | | | | As Adjusted |
| (In Millions, Except Per Share Amounts) |
| Adjusted EBITDA* | $ | 971.1 | | | | | | | $ | — | | | | | | | $ | — | | | | | | | | | $ | — | | | | | | | $ | 971.1 | |
| Depreciation and amortization | (273.9) | | | | | | | 6.1 | | | | | | | — | | | | | | | | | — | | | | | | | (267.8) | |
Interest expense and amortization of debt discounts and fees | (143.5) | | | | | | | — | | | | | | | — | | | | | | | | | — | | | | | | | (143.5) | |
| Stock-based compensation | (50.6) | | | | | | | — | | | | | | | — | | | | | | | | | — | | | | | | | (50.6) | |
| Loss on disposal or impairment of assets | (9.8) | | | | | | | — | | | | | | | — | | | | | | | | | — | | | | | | | (9.8) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| State regulatory change impact on noncontrolling interests | 2.2 | | | | | | | (2.2) | | | | | | | — | | | | | | | | | — | | | | | | | — | |
Change in fair market value of equity securities | 0.7 | | | | | | | — | | | | | | | — | | | | | | | | | (0.7) | | | | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Income from continuing operations before income tax expense | 496.2 | | | | | | | 3.9 | | | | | | | — | | | | | | | | | (0.7) | | | | | | | 499.4 | |
| Provision for income tax expense | (132.2) | | | | | | | (1.0) | | | | | | | 2.8 | | | | | | | | | 0.2 | | | | | | | (130.2) | |
Income from continuing operations attributable to Encompass Health | $ | 364.0 | | | | | | | $ | 2.9 | | | | | | | $ | 2.8 | | | | | | | | | $ | (0.5) | | | | | | | $ | 369.2 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Diluted earnings per share from continuing operations** | $ | 3.59 | | | | | | | $ | 0.03 | | | | | | | $ | 0.03 | | | | | | | | | $ | — | | | | | | | $ | 3.64 | |
| Diluted shares used in calculation | 101.3 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
* Reconciliation to GAAP provided on page 9
** Adjusted EPS may not sum across due to rounding.
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Income to Adjusted EBITDA
| | | | | | | | | | | | | | | | | | | | | | | |
| | Q4 | | Year Ended |
| | 2024 | | 2023 | | 2024 | | 2023 |
| (In Millions) |
| Net income | $ | 164.2 | | | $ | 119.1 | | | $ | 596.6 | | | $ | 463.0 | |
| (Income) loss from discontinued operations, net of tax,attributable to Encompass Health | (0.4) | | | 8.5 | | | 2.8 | | | 12.0 | |
| Net income attributable to noncontrolling interests included in continuing operations | (43.3) | | | (31.5) | | | (140.9) | | | (111.0) | |
| Provision for income tax expense | 37.6 | | | 37.2 | | | 150.2 | | | 132.2 | |
Interest expense and amortization of debt discounts and fees | 33.0 | | | 34.9 | | | 137.4 | | | 143.5 | |
| Depreciation and amortization | 78.0 | | | 70.1 | | | 299.6 | | | 273.9 | |
| Loss on early extinguishment of debt | 0.2 | | | — | | | 0.6 | | | — | |
| Loss on disposal or impairment of assets | 6.1 | | | 6.1 | | | 17.4 | | | 9.8 | |
| Stock-based compensation | 12.5 | | | 13.4 | | | 48.3 | | | 50.6 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| State regulatory change impact on noncontrolling interests | — | | | — | | | — | | | (2.2) | |
| Change in fair market value of equity securities | 1.7 | | | (2.8) | | | (1.0) | | | (0.7) | |
| Asset impairment impact on noncontrolling interests | — | | | — | | | (7.3) | | | — | |
| | | | | | | |
| Adjusted EBITDA | $ | 289.6 | | | $ | 255.0 | | | $ | 1,103.7 | | | $ | 971.1 | |
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
| | | | | | | | | | | | | | | | | | | | | | | |
| Q4 | | Year Ended |
| 2024 | | 2023 | | 2024 | | 2023 |
| (In Millions) |
| Net cash provided by operating activities | $ | 278.8 | | | $ | 201.0 | | | $ | 1,002.8 | | | $ | 850.8 | |
| Impact of discontinued operations | (0.6) | | | 11.4 | | | 3.1 | | | 16.0 | |
Net cash provided by operating activities of continuing operations | 278.2 | | | 212.4 | | | 1,005.9 | | | 866.8 | |
| Capital expenditures for maintenance | (50.8) | | | (87.1) | | | (184.6) | | | (216.9) | |
Distributions paid to noncontrolling interests of consolidated affiliates | (39.5) | | | (22.8) | | | (125.0) | | | (114.7) | |
| Items not indicative of ongoing operating performance: | | | | | | | |
| | | | | | | |
| | | | | | | |
| Transaction costs and related liabilities | 2.6 | | | (9.0) | | | (6.0) | | | (9.5) | |
| | | | | | | |
| Adjusted free cash flow | $ | 190.5 | | | $ | 93.5 | | | $ | 690.3 | | | $ | 525.7 | |
For the three months ended December 31, 2024, net cash used in investing activities was $203.7 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended December 31, 2024 was $150.9 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
For the three months ended December 31, 2023, net cash used in investing activities was $208.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended December 31, 2023 was $29.9 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, and cash dividends paid on common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
For the year ended December 31, 2024, net cash used in investing activities was $653.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the year ended December 31, 2024 was $330.6 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
For the year ended December 31, 2023, net cash used in investing activities was $602.8 million and resulted primarily from capital expenditures. Net cash used in financing activities during the year ended December 31, 2023 was $197.2 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, and cash dividends paid on common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, an infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health’s services, including based on any downturns in the economy, consumer confidence, or the capital markets; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; Encompass Health’s ability to realize construction cost savings from prefabrication of hospitals; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the cost of, or the decrease in the availability of, necessary supplies, such as personal protective equipment; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2024, when filed.
2024 Fourth Quarter Earnings Call February 7, 2025 Supplemental information
Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including the business outlook, guidance and growth targets, labor availability and costs, legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, such as the de novo pipeline, costs, growth and timelines, operational initiatives, dividend strategies, leverage, repurchases of securities, outstanding shares of common stock, effective tax rates, financial performance, financial assumptions and considerations, balance sheet and cash flow plans, market barriers to entry, and addressable market size. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the earnings release attached as Exhibit 99.1 to the Company’s Form 8-K dated February 6, 2025 (the “Q4 Earnings Release Form 8-K”), the Form 10-K for the year ended December 31, 2023, the Forms 10-Q for the quarters ended March 31, 2024, June 30, 2024, and September 30, 2024, the Form 10-K for the year ended December 31, 2024, when filed, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note regarding presentation of non-GAAP financial measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Q4 Earnings Release Form 8-K provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-looking statements
Encompass Health 3 Summary ................................................................................................................................................................................ 4 Revenue ................................................................................................................................................................................. 5 Adjusted EBITDA .................................................................................................................................................................. 6 Earnings per share ............................................................................................................................................................... 7-8 Adjusted free cash flow ..................................................................................................................................................... 9 2025 Guidance and guidance considerations ............................................................................................................... 10-11 Adjusted free cash flow assumptions ............................................................................................................................. 12 Uses of free cash flow ........................................................................................................................................................ 13 Appendix Map of locations ................................................................................................................................................................... 15 Growth targets, fundamentals and value drivers ........................................................................................................ 16 Development activity ......................................................................................................................................................... 17 Debt maturity profile and schedule ................................................................................................................................ 18-19 New-store/same-store growth .......................................................................................................................................... 20 Payment sources .................................................................................................................................................................. 21 Operational metrics ............................................................................................................................................................ 22 Share information ................................................................................................................................................................ 23 Reconciliations to GAAP ..................................................................................................................................................... 24-30 End notes ............................................................................................................................................................................... 31-32 Table of contents
Encompass Health 4 Summary Q4 Full Year ($ in millions, except per share data) 2024 2023 % △ 2024 2023 % △ Encompass Health Net operating revenue $ 1,405.0 $ 1,246.8 12.7 % $ 5,373.2 $ 4,801.2 11.9 % Adjusted EBITDA $ 289.6 $ 255.0 13.6 % $ 1,103.7 $ 971.1 13.7 % Adjusted EPS $ 1.17 $ 0.95 23.2 % $ 4.43 $ 3.64 21.7 % Adjusted free cash flow $ 190.5 $ 93.5 103.7 % $ 690.3 $ 525.7 31.3 % Reconciliations to GAAP provided on pages 24-30. 2024 Year in review u Capacity additions Ÿ Opened 6 de novo hospitals with a total of 280 beds and a 40-bed satellite hospital ü Net pre-opening and ramp up costs of $15.6 million Ÿ Added 107 beds to existing hospitals u Balance sheet Ÿ Net leverage of 2.2x compared to 2.7x at year-end 2023 Ÿ Redeemed $250 million of 5.75% Senior Notes due 2025 u Shareholder distributions Ÿ Paid cash dividends totaling $0.62 per share Ÿ Repurchased 358,837 shares of common stock for $31.1 million
Encompass Health 5 Revenue Q4 Q4 % Change* ($ in millions) 2024 2023 Net operating revenue: Inpatient $ 1,366.1 $ 1,216.8 12.3% Outpatient and other 38.9 30.0 29.7% Total revenue $ 1,405.0 $ 1,246.8 12.7% (Actual Amounts) Discharges 63,839 59,247 7.8% New-store discharge growth 2.0% Same-store discharge growth 5.8% Net patient revenue per discharge $ 21,399 $ 20,538 4.2% Revenue reserves related to bad debt as a percent of revenue 2.1 % 4.1 % (200) bps u Outpatient and other revenue includes an $8.7 million increase in provider tax revenues.(1) u Revenue reserves related to bad debt decreased 200 basis points due to strong collections of previously reviewed claims in Q4-24 and elevated bad debt in Q4-23. Ÿ Q4-23 bad debt included an approximately $22 million reserve related to appeals pending before the Departmental Appeals Board (DAB) and various federal courts.(2) These appeals primarily related to claims denied prior to 2018. *Except for Revenue reserves related to bad debt as a percent of revenue, which is increase (decrease) Refer to pages 31-32 for end notes.
Encompass Health 6 Adjusted EBITDA(3) Q4 % of Revenue Q4 % of Revenue($ in millions) 2024 2023 Net operating revenue $ 1,405.0 $ 1,246.8 Operating expenses: Salaries and benefits (756.8) 53.9 % (676.3) 54.2 % Other operating expenses(a) (200.3) 14.3 % (178.7) 14.3 % Supplies (62.3) 4.4 % (58.6) 4.7 % Occupancy costs (14.7) 1.0 % (14.0) 1.1 % Hospital operating expenses (277.3) 19.7 % (251.3) 20.2 % General and administrative expenses(b) (41.8) 3.0 % (36.9) 3.0 % Other income(c) 3.6 3.3 Equity in nonconsolidated affiliates 0.2 0.9 Noncontrolling interests in continuing operations (43.3) (31.5) Adjusted EBITDA $ 289.6 $ 255.0 Percent change 13.6 % Q4 Q4 ($ in millions) 2024 2023 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss on disposal or impairment of assets $ 6.1 $ 6.1 (b) Stock-based compensation and the change in fair market value of the non- qualified deferred comp plan $ 12.7 $ 16.2 (c) Change in fair market value of equity securities and the non-qualified deferred comp plan $ 1.5 $ (5.6) Reconciliations to GAAP provided on pages 24-30. Refer to pages 31-32 for end notes. u Other operating expenses includes a $5.8 million increase in provider tax expenses.(1)
Encompass Health 7 Earnings per share - as reported Q4 Year Ended ($ in millions, except per share data) 2024 2023 2024 2023 Adjusted EBITDA $ 289.6 $ 255.0 $ 1,103.7 $ 971.1 Depreciation and amortization(4) (78.0) (70.1) (299.6) (273.9) Interest expense and amortization of debt discounts and fees (33.0) (34.9) (137.4) (143.5) Stock-based compensation (12.5) (13.4) (48.3) (50.6) Loss on disposal or impairment of assets(5) (6.1) (6.1) (17.4) (9.8) 160.0 130.5 601.0 493.3 Items not indicative of ongoing operating performance: Loss on early extinguishment of debt(6)(7) (0.2) — (0.6) — State regulatory change impact on noncontrolling interests(4) — — — 2.2 Change in fair market value of equity securities (1.7) 2.8 1.0 0.7 Asset impairment impact on noncontrolling interests(5) — — 7.3 — Pre-tax income 158.1 133.3 608.7 496.2 Income tax expense (37.6) (37.2) (150.2) (132.2) Income from continuing operations* $ 120.5 $ 96.1 $ 458.5 $ 364.0 Diluted shares (see page 23) 102.3 101.5 102.2 101.3 Diluted earnings per share* $ 1.18 $ 0.94 $ 4.49 $ 3.59 * Earnings per share are determined using income from continuing operations attributable to Encompass Health. Reconciliations to GAAP provided on pages 24-30. Refer to pages 31-32 for end notes.
Encompass Health 8 Adjusted earnings per share(8) Refer to pages 31-32 for end notes. Q4 Year Ended 2024 2023 2024 2023 Diluted earnings per share, as reported $ 1.18 $ 0.94 $ 4.49 $ 3.59 Adjustments, net of tax: Asset impairment impact(5) — — 0.02 — Income tax adjustments(9) (0.03) 0.03 (0.08) 0.03 State regulatory change impact(4) — — — 0.03 Change in fair market value of equity securities 0.01 (0.02) (0.01) — Adjusted earnings per share* $ 1.17 $ 0.95 $ 4.43 $ 3.64 u Adjusted earnings per share removes from GAAP earnings per share the impact of items the Company believes are not indicative of its ongoing operating performance. * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 27-30.
Encompass Health 9 $525.7 $132.6 $50.6 $6.3 $(57.2) $32.3 $690.3 Adjusted free cash flow FY 2023 Adjusted EBITDA Working capital and other Cash interest payments Cash tax payments, net of refunds Maintenance capital expenditures Adjusted free cash flow FY 2024 2024 Adjusted free cash flow(10) Reconciliations to GAAP provided on pages 24-30. Refer to pages 31-32 for end notes. ($ in millions) u Decreased working capital primarily due to: Ÿ Lower accounts receivable Ÿ An increase in liabilities including group medical and other self-insured reserves, provider taxes and cost report settlements u Increased cash taxes primarily due to higher income, the phase-out of bonus depreciation and 2023 cash taxes benefiting from an $11 million overpayment in 2022
Encompass Health 10 2025 Guidance 2024 Actuals 2025 Guidance ($ in millions, except per share data) Net Operating Revenue $5,373.2 $5,800 to $5,900 Adjusted EBITDA(3) $1,103.7 $1,160 to $1,200 Adjusted earnings per share from continuing operations attributable to Encompass Health(8) $4.43 $4.67 to $4.96 Reconciliations to GAAP provided on pages 24-30. Refer to pages 31-32 for end notes.
Encompass Health 11 2025 Guidance considerations u Pricing Ÿ Medicare pricing increase of 3.3% for Q1 through Q3 and an estimated 2.5% to 3.0% for Q4 Ÿ Managed Care pricing increase of 2.0% to 3.0% Ÿ Bad debt reserves of 2.0% to 2.5% of revenue u Labor Ÿ SWB per FTE* increase of 3.25% to 3.75% u Capacity additions Ÿ 7 de novo hospitals with 340 beds and a 50-bed satellite hospital(11) ü Net pre-opening and ramp-up costs of $18 million to $22 million (inclusive of costs associated with 2026 openings incurred in 2025) Ÿ Approximately 100 beds to existing hospitals u Corporate Ÿ Adjusted EBITDA impact of $11.5 million to $13.5 million ü Oracle Fusion implementation costs of $5.5 million to $6.5 million ($2.3 million in 2024) ü Addition of Augusta hospital to Piedmont joint venture increasing income attributable to noncontrolling interests (NCI) by $6.0 million to $7.0 million ($3.2 million in 2024) Ÿ Tax rate of approximately 26% Ÿ Diluted share count of approximately 103 million shares Refer to pages 31-32 for end notes. *Includes contract labor and sign-on and shift bonuses
Encompass Health 12 Adjusted free cash flow(10) assumptions Certain cash flow items ($ in millions) 2024 Actuals 2025 Assumptions Cash interest payments (net of amortization of debt discounts and fees) $127.7 $110 to $120 Cash payments for income taxes, net of refunds $163.8 $155 to $175 Working capital and other $(62.7) $30 to $50 Maintenance CAPEX $184.6 $215 to $225 Adjusted free cash flow $690.3 $590 to $690 Increased working capital due to growth in revenue and normalized growth in group medical reserves Reconciliations to GAAP provided on pages 24-30. Refer to pages 31-32 for end notes. Increased maintenance CAPEX related to major renovation projects and programmatic hospital asset replacements Cash tax payments include an increase in pre-tax income offset by overpayment from 2024 Decreased cash interest payments due to repayment of $250 million of Senior Notes during 2024
Encompass Health 13 Uses of free cash flow ($ in millions) 2024 Actuals 2025 Assumptions Growth in core business IRF bed expansions $96.8 $145 to $155 New IRFs - De novos 358.1 380 to 390 - Replacement IRFs and other 3.0 TBD $457.9 $525 to $545 Debt reduction Change in total debt(12) $214.8 TBD Shareholder distributions Cash dividends on common stock $62.8 ~ $68 Common stock repurchases $31.1 TBD Refer to pages 31-32 for end notes. Ÿ ~$489 million remaining under current authorization as of December 31, 2024(13)
Appendix
Encompass Health 15 Rehabilitation hospitals “IRFs” De novos under development* * De novos under development - previously announced de novo hospitals under development as of February 6, 2025 ** IRFs under development include de novo and remote and satellite locations(11) Refer to pages 31-32 for end notes. Encompass Health Largest owner and operator of rehabilitation hospitals Company profile as of 12/31/24 166 Rehabilitation hospitals “IRFs” 65 are joint ventures 17 38 IRFs under development** States and Puerto Rico Key statistics trailing four quarters ~248,500 patient discharges ~$5.4 Billion in revenue ~40,200 employees 2025 Fortune World’s Most Admired CompaniesTM 2025 Forbes Most Trusted Companies in America 2024 Becker’s Top Places to Work in Healthcare Fortune © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World’s Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.
Encompass Health 16 Growth targets, fundamentals and value drivers u 2023 - 2027 Growth targets Ÿ 6 to 10 de novos per year Ÿ 80 to 120 bed additions per year Ÿ 6% to 8% discharge CAGR u Large, under penetrated, and growing inpatient rehabilitation market Ÿ Large addressable market indicated by low conversion rate of presumptively eligible inpatient rehabilitation patients Ÿ Favorable demographics driving increased demand for rehabilitation services Ÿ Unparalleled clinical expertise for treating inpatient rehabilitation conditions with consistent delivery of high-quality, cost-effective care Ÿ De novo and bed addition strategy delivers attractive financial returns Ÿ Cash flow and capital availability to fund capacity additions Ÿ Fragmented sector presents unit acquisition and joint venture opportunities Ÿ Significant barriers to entry and economies of scale Ÿ Resilient business model with focus on non-discretionary conditions occurring predominantly in an aging population u Shareholder distributions Ÿ Cash dividend (currently $0.17 per share per quarter) Ÿ Approximately $489 million remaining under current stock repurchase authorization as of December 31, 2024(13) Refer to pages 31-32 for end notes.
Encompass Health 17 Inpatient Rehabilitation Hospitals opened or under development Joint venture Expected open date # of new beds 2024 2025 2026 2027 De novos* Kissimmee, FL 50 — — — Atlanta, GA ü 40 — — — Louisville, KY ü 40 — — — Johnston, RI 50 — — — Fort Mill, SC 39 — — — Houston, TX 61 — — — 1 Athens, GA ü 1Q25 — 40 — — 2 Fort Myers, FL ü 2Q25 — 60 — — 3 Daytona Beach, FL 2Q25 — 50 — — 4 Danbury, CT 3Q25 — 40 — — 5 Lake Worth, FL 4Q25 — 50 — — 6 St. Petersburg, FL 4Q25 — 50 — — 7 Amarillo, TX 4Q25 — 50 — — 8 Irmo, SC — — 50 — 9 Concordville, PA — — 50 — 10 Loganville, GA ü — — 40 — 11 Norristown, PA — — 50 — 12 Avondale, AZ — — 60 — 13 San Antonio, TX — — 50 — 14 Wesley Chapel, FL — — — 50 15 Palm Beach Gardens, FL — — — 50 16 Bangor, ME — — — 50 Remote and satellite(11)* Ballwin, MO (Town & Country) ü 40 — — — 17 Wildwood, FL (in The Villages, FL) 3Q25 — 50 — — Other bed additions 107 ~100 ~100 ~100 *All dates are tentative and subject to change 427 ~490 ~400 ~250 Development activity 4Q 2024 Development activity highlights uOpened de novos # of beds JV Ÿ Houston, TX 61 Beds added to existing hospitals 22 Announced de novos # of beds JV Ÿ Wesley Chapel, FL 50 Ÿ Bangor, ME 50 IRF development projects announced and underway** 17 ** IRFs under development include de novo and remote and satellite locations(11) Refer to pages 31-32 for end notes.
Encompass Health 18 2024 2025 2026 2027 2028 2029 2030 2031 * This chart does not include ~$318 of finance lease obligations or ~$95 of other notes payable. See the debt schedule on page 19. Debt maturity profile - face value ($ in millions) Revolver capacity $800 Senior Notes 4.75% $800 Senior Notes 4.5% As of December 31, 2024* $944 Available $20 Drawn + $36 reserved for LCs Callable at par Callable at 101.125 $400 Senior Notes 4.625% Callable beginning April 2026 u Redeemed $250 million of 5.75% Senior Notes due 2025 in 2024(6)(7) $100 Senior Notes 5.75% Callable beginning February 2025 Refer to pages 31-32 for end notes.
Encompass Health 19 Debt schedule Change in December 31, December 31, Debt vs. ($ in millions) 2024 2023 YE 2023 Advances under $1 billion revolving credit facility $ 20.0 $ — $ 20.0 Bonds Payable: 5.75% Senior Notes due 2025 99.8 348.5 (248.7) 4.50% Senior Notes due 2028 788.4 785.0 3.4 4.75% Senior Notes due 2030 784.2 781.5 2.7 4.625% Senior Notes due 2031 392.5 391.5 1.0 Other notes payable 94.5 66.0 28.5 Finance lease obligations 318.4 340.1 (21.7) Long-term debt $ 2,497.8 $ 2,712.6 $ (214.8) Debt to Adjusted EBITDA 2.3 x 2.8 x Leverage net of cash and cash equivalents 2.2 x 2.7 x Reconciliations to GAAP provided on pages 24-30. The leverage ratio for 2024 stated in terms of the most comparable GAAP measurement would be Debt to Net cash provided by operating activities: 2.5x The leverage ratio for 2023 stated in terms of the most comparable GAAP measurement would be Debt to Net cash provided by operating activities: 3.2x
Encompass Health 20 0.0% 5.0% 10.0% 15.0% 20.0% New-store/same-store growth Johnston, RI (50 beds) Fort Mill, SC (39 beds) Discharges Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 New store 3.8% 3.3% 3.4% 3.1% 3.5% 3.6% 3.0% 3.0% 3.3% 1.9% 2.0% 2.0% Same store(14) 3.8% 1.6% 4.1% 4.2% 5.9% 6.2% 4.3% 5.3% 6.7% 4.8% 6.8% 5.8% Total by quarter 7.6% 4.9% 7.5% 7.3% 9.4% 9.8% 7.3% 8.3% 10.0% 6.7% 8.8% 7.8% Total by year 6.8% 8.7% 8.3% Same store by year(14) 3.1% 4.8% 5.6% Shiloh, IL (40 beds) St. Augustine, FL (40 beds) Libertyville, IL (60 beds) Moline, IL (40 beds) Naples, FL (50 beds) Grand Forks, ND (40 beds) Lakeland, FL (50 beds) Cape Coral, FL (40 beds) Jacksonville, FL (50 beds) Knoxville, TN (73 beds) Owasso, OK (40 beds) Clermont, FL (50 beds) Bowie, MD (60 beds) Columbus, GA (40 beds) Prosper, TX (40 beds) Fitchburg, WI (56 beds) Kissimmee, FL (50 beds) Atlanta, GA (40 beds) Louisville, KY (40 beds) Refer to pages 31-32 for end notes. Houston, TX (61 beds)
Encompass Health 21 Payment sources (percent of revenues) Q4 Full Year 2024 2023 2024 2023 Medicare 65.6 % 65.7 % 65.1 % 65.0 % Medicare Advantage 16.5 % 16.0 % 16.8 % 16.2 % Managed care 10.5 % 10.8 % 10.8 % 11.1 % Medicaid 3.2 % 3.6 % 3.3 % 4.0 % Other third-party payors 0.8 % 0.8 % 0.8 % 0.9 % Workers’ compensation 0.5 % 0.5 % 0.5 % 0.5 % Patients 0.3 % 0.4 % 0.3 % 0.3 % Other income 2.6 % 2.2 % 2.4 % 2.0 % Total 100.0 % 100.0 % 100.0 % 100.0 %
Encompass Health 22 Operational metrics Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2024 2024 2024 2024 2023 2023 2023 2023 2024 2023 (In Millions) Net patient revenue- inpatient $ 1,366.1 $ 1,316.2 $ 1,265.5 $ 1,282.7 $ 1,216.8 $ 1,180.5 $ 1,162.3 $ 1,134.2 $ 5,230.5 $ 4,693.8 Net patient revenue- outpatient and other revenues 38.9 34.8 35.7 33.3 30.0 26.4 24.8 26.2 142.7 107.4 Net operating revenues $ 1,405.0 $ 1,351.0 $ 1,301.2 $ 1,316.0 $ 1,246.8 $ 1,206.9 $ 1,187.1 $ 1,160.4 $ 5,373.2 $ 4,801.2 (Actual Amounts) Discharges(15) 63,839 62,715 60,833 61,111 59,247 57,665 57,011 55,557 248,498 229,480 Net patient revenue per discharge $ 21,399 $ 20,987 $ 20,803 $ 20,990 $ 20,538 $ 20,472 $ 20,387 $ 20,415 $ 21,048 $ 20,454 Outpatient visits 26,434 28,544 29,312 29,744 29,627 28,604 30,752 31,852 114,034 120,835 Average length of stay 12.0 12.2 12.2 12.3 12.3 12.4 12.3 12.5 12.2 12.4 Occupancy % 75.3 % 75.4 % 74.5 % 76.7 % 73.4 % 72.8 % 72.4 % 73.4 % 74.6 % 72.1 % # of licensed beds 11,094 11,041 10,948 10,781 10,778 10,677 10,611 10,510 11,094 10,778 Occupied beds 8,354 8,325 8,156 8,269 7,911 7,773 7,682 7,714 8,276 7,771 Full-time equivalents (FTEs) - internal 28,188 27,938 27,297 27,209 26,713 26,112 25,453 25,122 27,658 25,850 Contract labor FTEs 394 430 450 434 378 388 476 459 427 425 Total FTEs(16) 28,582 28,368 27,747 27,643 27,091 26,500 25,929 25,581 28,085 26,275 EPOB(17) 3.42 3.41 3.40 3.34 3.42 3.41 3.38 3.32 3.39 3.38 Refer to pages 31-32 for end notes.
Encompass Health 23 Share information Weighted Average for the Period Q4 Full Year (in millions) 2024 2023 2024 2023 2022 Basic shares outstanding 100.0 99.5 99.9 99.5 99.2 Restricted stock awards, dilutive stock options, and restricted stock units 2.3 2.0 2.3 1.8 1.2 Diluted shares outstanding 102.3 101.5 102.2 101.3 100.4 End of Period Q4 Full Year (in millions) 2024 2023 2024 2023 2022 Basic shares outstanding 100.8 100.3 100.8 100.3 99.8
Encompass Health 24 Net cash provided by operating activities reconciled to Adjusted EBITDA(3) Q4 Full Year ($ in millions) 2024 2023 2024 2023 Net cash provided by operating activities $ 278.8 $ 201.0 $ 1,002.8 $ 850.8 Interest expense and amortization of debt discounts and fees 33.0 34.9 137.4 143.5 (Loss) gain on sale of investments, excluding impairments (3.1) 5.5 2.7 4.6 Equity in net income of nonconsolidated affiliates 0.2 0.9 3.0 3.2 Net income attributable to noncontrolling interests in continuing operations (43.3) (31.5) (140.9) (111.0) Amortization of debt-related items (2.4) (2.4) (9.7) (9.5) Distributions from nonconsolidated affiliates (0.9) (1.0) (4.0) (1.6) Current portion of income tax expense 29.0 30.4 139.5 128.3 Change in assets and liabilities (2.8) 8.6 (21.9) (50.3) Cash (provided by) used in operating activities of discontinued operations (0.6) 11.4 3.1 16.0 State regulatory change impact on noncontrolling interests(4) — — — (2.2) Asset impairment impact on noncontrolling interests(5) — — (7.3) — Change in fair market value of equity securities 1.7 (2.8) (1.0) (0.7) Adjusted EBITDA $ 289.6 $ 255.0 $ 1,103.7 $ 971.1 Refer to pages 31-32 for end notes.
Encompass Health 25 Reconciliation of net income to Adjusted EBITDA(3) Q4 Full Year ($ in millions) 2024 2023 2024 2023 Net income $ 164.2 $ 119.1 $ 596.6 $ 463.0 (Income) loss from discontinued operations, net of tax, attributable to Encompass Health (0.4) 8.5 2.8 12.0 Net income attributable to noncontrolling interests included in continuing operations (43.3) (31.5) (140.9) (111.0) Provision for income tax expense 37.6 37.2 150.2 132.2 Interest expense and amortization of debt discounts and fees 33.0 34.9 137.4 143.5 Depreciation and amortization(4) 78.0 70.1 299.6 273.9 Loss on early extinguishment of debt(6)(7) 0.2 — 0.6 — Loss on disposal or impairment of assets(5) 6.1 6.1 17.4 9.8 Stock-based compensation 12.5 13.4 48.3 50.6 State regulatory change impact on noncontrolling interests(4) — — — (2.2) Change in fair market value of equity securities 1.7 (2.8) (1.0) (0.7) Asset impairment impact on noncontrolling interests(5) — — (7.3) — Adjusted EBITDA $ 289.6 $ 255.0 $ 1,103.7 $ 971.1 Refer to pages 31-32 for end notes.
Encompass Health 26 Reconciliation of net cash provided by operating activities to adjusted free cash flow(10) Q4 Full Year ($ in millions) 2024 2023 2024 2023 Net cash provided by operating activities $ 278.8 $ 201.0 $ 1,002.8 $ 850.8 Impact of discontinued operations (0.6) 11.4 3.1 16.0 Net cash provided by operating activities of continuing operations 278.2 212.4 1,005.9 866.8 Capital expenditures for maintenance (50.8) (87.1) (184.6) (216.9) Distributions paid to noncontrolling interests of consolidated affiliates (39.5) (22.8) (125.0) (114.7) Items not indicative of ongoing operating performance: Transaction costs and related liabilities 2.6 (9.0) (6.0) (9.5) Adjusted free cash flow $ 190.5 $ 93.5 $ 690.3 $ 525.7 Cash dividends on common stock $ 17.0 $ 14.9 $ 62.8 $ 60.4 Refer to pages 31-32 for end notes.
Encompass Health 27 Adjusted EPS(8) - Q4 2024 For the Three Months Ended December 31, 2024 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 289.6 $ — $ — $ — $ 289.6 Depreciation and amortization (78.0) — — — (78.0) Interest expense and amortization of debt discounts and fees (33.0) — — — (33.0) Stock-based compensation (12.5) — — — (12.5) Loss on disposal or impairment of assets (6.1) — — — (6.1) Loss on early extinguishment of debt(7) (0.2) 0.2 — — — Change in fair market value of equity securities (1.7) — — 1.7 — Income from continuing operations before income tax expense 158.1 0.2 — 1.7 160.0 Provision for income tax expense (37.6) (0.1) (2.6) (0.4) (40.7) Income from continuing operations attributable to Encompass Health $ 120.5 $ 0.1 $ (2.6) $ 1.3 $ 119.3 Diluted earnings per share from continuing operations* $ 1.18 $ — $ (0.03) $ 0.01 $ 1.17 Diluted shares used in calculation 102.3 * Adjusted EPS may not sum across due to rounding. Refer to pages 31-32 for end notes.
Encompass Health 28 For the Three Months Ended December 31, 2023 Adjustments As Reported Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 255.0 $ — $ — $ 255.0 Depreciation and amortization (70.1) — — (70.1) Interest expense and amortization of debt discounts and fees (34.9) — — (34.9) Stock-based compensation (13.4) — — (13.4) Loss on disposal or impairment of assets (6.1) — — (6.1) Change in fair market value of equity securities 2.8 — (2.8) — Income from continuing operations before income tax expense 133.3 — (2.8) 130.5 Provision for income tax expense (37.2) 2.9 0.7 (33.6) Income from continuing operations attributable to Encompass Health $ 96.1 $ 2.9 $ (2.1) $ 96.9 Diluted earnings per share from continuing operations* $ 0.94 $ 0.03 $ (0.02) $ 0.95 Diluted shares used in calculation 101.5 Adjusted EPS(8) - Q4 2023 * Adjusted EPS may not sum across due to rounding. Refer to pages 31-32 for end notes.
Encompass Health 29 Adjusted EPS(8) - 2024 For the Year Ended December 31, 2024 Adjustments As Reported Asset Impairment Impact Loss on Early Exting. of Debt Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 1,103.7 $ — $ — $ — $ — $ 1,103.7 Depreciation and amortization (299.6) — — — — (299.6) Interest expense and amortization of debt discounts and fees (137.4) — — — — (137.4) Stock-based compensation (48.3) — — — — (48.3) Loss on disposal or impairment of assets(5) (17.4) 10.4 — — — (7.0) Loss on early extinguishment of debt(6)(7) (0.6) — 0.6 — — — Change in fair market value of equity securities 1.0 — — — (1.0) — Asset impairment impact on noncontrolling interests(5) 7.3 (7.3) — — — — Income from continuing operations before income tax expense 608.7 3.1 0.6 — (1.0) 611.4 Provision for income tax expense (150.2) (1.3) (0.2) (7.7) 0.3 (159.1) Income from continuing operations attributable to Encompass Health $ 458.5 $ 1.8 $ 0.4 $ (7.7) $ (0.7) $ 452.3 Diluted earnings per share from continuing operations* $ 4.49 $ 0.02 $ — $ (0.08) $ (0.01) $ 4.43 Diluted shares used in calculation 102.2 * Adjusted EPS may not sum across due to rounding. Refer to pages 31-32 for end notes.
Encompass Health 30 For the Year Ended December 31, 2023 Adjustments As Reported State Regulatory Change Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 971.1 $ — $ — $ — $ 971.1 Depreciation and amortization(4) (273.9) 6.1 — — (267.8) Interest expense and amortization of debt discounts and fees (143.5) — — — (143.5) Stock-based compensation (50.6) — — — (50.6) Loss on disposal or impairment of assets (9.8) — — — (9.8) State regulatory change impact on noncontrolling interests(4) 2.2 (2.2) — — — Change in fair market value of equity securities 0.7 — — (0.7) — Income from continuing operations before income tax expense 496.2 3.9 — (0.7) 499.4 Provision for income tax expense (132.2) (1.0) 2.8 0.2 (130.2) Income from continuing operations attributable to Encompass Health $ 364.0 $ 2.9 $ 2.8 $ (0.5) $ 369.2 Diluted earnings per share from continuing operations* $ 3.59 $ 0.03 $ 0.03 $ — $ 3.64 Diluted shares used in calculation 101.3 Adjusted EPS(8) - 2023 * Adjusted EPS may not sum across due to rounding. Refer to pages 31-32 for end notes.
Encompass Health 31 End notes Reconciliations to GAAP provided on pages 24-30. (1) Provider taxes are amounts paid by us to fund, in part, state Medicaid programs. We have historically used the term “provider tax revenues” to represent all amounts received in connection with state Medicaid programs that are not included in the specific Medicaid claim reimbursements we receive. These amounts include state directed and supplemental payment programs associated with Medicaid. We have used the term “net provider tax revenues” to represent the difference between provider taxes paid and the “provider tax revenues” received. (2) During Q4 2023, we recorded an additional reserve totaling approximately $22 million related to appeals pending before the Departmental Appeals Board (DAB) and several federal district courts. The increase in reserve was driven primarily by an increase in unfavorable adjudication outcomes experienced at the DAB during the second half of 2023 and largely offsets the remaining net carrying value of these claims. These appeals relate to claims denied primarily prior to 2018. This adjustment does not impact our reserve methodology for ongoing claims audit programs, including Targeted Probe and Educate (“TPE”) and Review Choice Demonstration (“RCD”) programs. We will continue to pursue ongoing appeals before the DAB and federal district courts where economically beneficial. The impact of the reserve on Q4 2023 Adjusted EBITDA was approximately $16 million, net of noncontrolling interest expense. (3) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. (4) In May of 2023, the governor of South Carolina signed into law S.164, which repealed the requirement of certain healthcare providers to obtain and/or maintain a certificate of need (“CON”). As a result of this repeal, in Q2 2023 we accelerated amortization of approximately $6 million in remaining carrying value of our South Carolina CON assets, increasing depreciation and amortization expense by approximately $6 million and reducing noncontrolling interest in continuing operations by approximately $2 million (related to our joint venture partner’s share of income at one impacted location). The impact of these adjustments have been excluded from the calculation of Adjusted EBITDA and adjusted earnings per share in the second quarter of 2023 given the non-recurring nature of the CON repeal (Florida is the only other state in recent history to repeal its CON law) is not indicative of ongoing operating performance. (5) In January 2024, we received notice that our joint venture partner, Hospital Sisters Health System, intended to close its acute-care hospital, Sacred Heart Hospital in Eau Claire, WI, in which our joint venture inpatient rehabilitation hospital is located. We closed that joint venture hospital in February 2024 and incurred a one-time impairment charge of $10.4 million. The impact to net income attributable to Encompass Health during the twelve months ended December 31, 2024 resulting from the impairment was $1.8 million after reductions for net income attributable to noncontrolling interests of $7.3 million and the provision for income tax expense of $1.3 million. (6) In the third quarter of 2024, the Company redeemed $150 million of its 5.75% Senior Notes due 2025. The redemption was completed at 100% of par using cash on hand. As a result of the redemption, the Company recorded a $0.4 million loss on early extinguishment of debt in the third quarter of 2024. (7) In the fourth quarter of 2024, the Company redeemed $100 million of its 5.75% Senior Notes due 2025. The redemption was completed at 100% of par using cash on hand. As a result of the redemption, the Company recorded a $0.2 million loss on early extinguishment of debt in the fourth quarter of 2024.
Encompass Health 32 End notes (continued) (8) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims and windfall tax benefits), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. (9) Income tax adjustments for the fourth quarter and year ended 2024 relate primarily to removal of windfall tax benefits from GAAP earnings per share. Income tax adjustments for the fourth quarter and year ended 2023 relate primarily to state tax expense associated with the spin-off of Enhabit removed from GAAP earnings per share. (10) The definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, distributions to noncontrolling interests, and certain items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. (11) Our inpatient rehabilitation hospitals (“IRFs”) may operate one or more satellite and/or remote locations. Satellite and remote locations are located proximate to one of our existing IRFs but do not have a separate Medicare provider number. As such, they are considered a bed addition, are included in same store results from the day of opening, and are not included in our count of total open hospitals. As of December 31, 2024, we operate 11 satellite and remote locations. (12) Cash used for net debt redemptions were $242.1 million during the twelve months ended December 31, 2024. (13) On October 28, 2013, the Company announced its board of directors authorized the repurchase of up to $200 million of its common stock. On February 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from $200 million to $250 million. As of June 30, 2018, the remaining repurchase authorization was approximately $58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. As of June 30, 2024, the remaining repurchase authorization was approximately $181 million. On July 24, 2024, the Company’s board approved resetting the aggregate common stock repurchase authorization to $500 million. As of December 31, 2024, the remaining repurchase authorization was approximately $489 million. (14) Same-store comparisons are calculated based on hospitals open throughout both the full current periods and prior periods presented. These comparisons include the financial results of market consolidation transactions and capacity expansions (including the addition of satellite and remote hospitals) in existing markets. (15) Represents discharges from 166 consolidated hospitals in Q4 2024; 165 consolidated hospitals in Q3 2024; 163 consolidated hospitals in Q2 2024; 160 consolidated hospitals in Q1 2024; 161 consolidated hospitals in Q4 2023; 159 consolidated hospitals in Q3 2023; 158 consolidated hospitals in Q2 2023; and 156 consolidated hospitals in Q1 2023. (16) Total full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include full-time equivalents related to contract labor. (17) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of total full-time equivalents, including full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. Reconciliations to GAAP provided on pages 24-30.
v3.25.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
